Phong Duong, PharmD

Linkedin Team icon

VP, Global Market Access and Health Economics

Phong works with cross-functional stakeholders to develop and execute the integrated value evidence plan, market access and pricing reimbursement strategy for all of our pipeline assets during their various development phases. His work and expertise contributes to the comprehensive launch readiness of MM-120 by ensuring that global payers fully understand and value its clinical and economic benefits.

Phong brings experience in commercial product development and new product launches in both chronic and acute disease states, across a number of therapeutic areas including neurology and psychiatry. Prior to joining MindMed, Phong spent 26 years at Merck in a number of research, marketing, commercial operation roles with increasing responsibilities. Prior to his tenure at Merck, Phong served as a health policy and epidemiology consultant at SmithKline and Beecham.

Phong holds a Doctor of Pharmacy degree from the Philadelphia College of Pharmacy and Science and a Bachelor’s degree in Pharmacy Science from Temple University. He completed his post-graduate fellowship in health policy and pharmaco-economics at Thomas Jefferson University School of Medicine.

Paul Summergrad, MD

Professor of Psychiatry and Medicine at Tufts University School of Medicine and Chairman Emeritus of the department of psychiatry at Tufts Medical Center

Nzinga Harrison, MD

Co-Founder & Chief Medical Officer, Eleanor Health

Carol Vallone

Chair of the Board of Directors, Member of Compensation Committee, Member of Audit Committee

Andreas Krebs

Vice Chair of the Board of Directors, Member of Nomination & Governance Committee, Member of Audit Committee

David Gryska

Board Director, Chair of Audit Committee

Roger Crystal, MD

Board Director, Chair of Nomination & Governance Committee, Member of Compensation Committee

Robert Barrow

Chief Executive Officer and Board Director

Suzanne Bruhn, PhD

Board Director, Chair of Compensation Committee, Member of Nomination & Governance Committee

Miri Halperin Wernli, PhD

Executive President

Daniel Karlin, MD, MA

Chief Medical Officer

Mark Sullivan, JD

Chief Legal Officer and Corporate Secretary

Francois Lilienthal, MD, MBA

Chief Commercial Officer

Carrie Liao, CPA

Chief Accounting Officer

Stephanie Fagan, MS

Chief Corporate Affairs Officer

Gregg Pratt, PhD

Chief Regulatory and Quality Assurance Officer

Robert Malenka, MD, PhD

Chairman of the Scientific Advisory Board, Nancy Friend Pritzker Professor in Psychiatry and Behavioral Sciences at Stanford University

Peter Bergethon, MD

Member, Scientific Advisory Board VP, Head of Quantitative & Clinical Technologies, Biogen, Inc.

Robert Dworkin, PhD

Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry at University of Rochester

Maurizio Fava, MD

Psychiatrist-in-Chief of the Massachusetts General Hospital (MGH)

Carole Abel, MBA

VP, Programs and Portfolio Office (PPO)

Peter Mack, PhD

VP, Pharmaceutical Development

Michael Seggev

VP, Global Marketing, Strategic Insights and Digital Innovation

Rafael Muniz, MD

VP, Global Medical Affairs

Phong Duong, PharmD

VP, Global Market Access and Health Economics

Maria Oquendo, MD, PhD

Ruth Meltzer Professor and Chairman of Psychiatry at University of Pennsylvania, Psychiatrist-in-Chief at the Hospital of the University of Pennsylvania

Matthias Liechti, MD, PhD

Scientific Collaborator & Advisor

Kim PC Kuypers, PhD

Scientific Collaborator & Advisor

Peter Gasser, MD

Clinical Advisor